Abstract
A phase 1/2 safety and efficacy study of TAK‐754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have